Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Resectable/Potentially Resectable NSCLC”

22 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 22 results

Not applicableLooking for participantsNCT06448793
What this trial is testing

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb 55
Testing effectiveness (Phase 2)Study completedNCT00043108
What this trial is testing

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Fox Chase Cancer Center 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT03838159
What this trial is testing

NADIM II: Neo-Adjuvant Immunotherapy

Who this might be right for
Non Small Cell Lung Cancer
Fundación GECP 90
Not applicableActive Not RecruitingNCT06243679
What this trial is testing

The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC

Who this might be right for
Resectable/Potentially Resectable NSCLC
Xiangya Hospital of Central South University 100
Early research (Phase 1)UnknownNCT05157542
What this trial is testing

Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

Who this might be right for
Stage III Non-small Cell Lung Cancer
Juan LI, MD 9
Testing effectiveness (Phase 2)Looking for participantsNCT07323056
What this trial is testing

Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

Who this might be right for
EGFR-mutant Non-small Cell Lung CancerPotentially Resectable
Shanghai Pulmonary Hospital, Shanghai, China 36
Large-scale testing (Phase 3)Study completedNCT00002930
What this trial is testing

PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery

Who this might be right for
Esophageal CancerLung Cancer
Memorial Sloan Kettering Cancer Center 75
Not applicableLooking for participantsNCT04324151
What this trial is testing

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Hunan Province Tumor Hospital 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT04379739
What this trial is testing

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 89
Large-scale testing (Phase 3)Study completedNCT00136890
What this trial is testing

PET Imaging in Potentially Surgically Resectable Non-small Cell Lung Cancers

Who this might be right for
Non-small-cell Lung Carcinoma
Ontario Clinical Oncology Group (OCOG) 337
Testing effectiveness (Phase 2)Looking for participantsNCT06424899
What this trial is testing

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Zeng Jian 92
Testing effectiveness (Phase 2)Active Not RecruitingNCT07274761
What this trial is testing

Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.

Who this might be right for
Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung CancerNon Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05891080
What this trial is testing

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Who this might be right for
Stage III Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 124
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06644313
What this trial is testing

Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Potentially Resectable MET-altered Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 31
Large-scale testing (Phase 3)Looking for participantsNCT07016126
What this trial is testing

D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Guangdong Provincial People's Hospital 70
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06282536
What this trial is testing

Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial

Who this might be right for
Potentially Resectable ALK Positive Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04304248
What this trial is testing

Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Hao Long 30
Testing effectiveness (Phase 2)Looking for participantsNCT03694236
What this trial is testing

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Who this might be right for
Potentially Resectable Stage II/IIIa NSCLC
Yonsei University 39
Not applicableUnknownNCT06081777
What this trial is testing

Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer

Who this might be right for
NSCLC
Peking University Cancer Hospital & Institute 65
Testing effectiveness (Phase 2)Active Not RecruitingNCT04326153
What this trial is testing

Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer

Who this might be right for
IIIA Stage Non-small Cell Lung Cancer
The First Hospital of Jilin University 30
Load More Results